ClinicalTrials.gg
CompletedNCT02052310HimalayasUpdated Oct 1, 2021Results posted

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

A Phase 3 interventional study of Roxadustat and Epoetin Alfa in Anemia in Incident Dialysis Patients, sponsored by FibroGen. Completed at 113 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-01.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,043
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
3rd of 43
1,043 · median 154
Started
2014
with 4 others
Phase 3
25 of 43
1 open now
Registered
12th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 3rd largest by enrollment, is one of 5 that started in 2014, is one of 25 in phase 3, and was the 12th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.

Read the detailed description

There is a screening period of up to 6 weeks, a treatment period of a minimum of 52 weeks and a maximum of approximately up to 3 years after last participant is randomized, and a post-treatment follow-up period of 4 weeks. Participants will be randomized in a 1:1 ratio to receive either open-label roxadustat or epoetin alfa (active control).

03

Conditions studied

  • Anemia in Incident Dialysis Patients

Keywords

  • Anemia
  • Chronic Kidney Disease
  • Hemoglobin
  • End-Stage Renal Disease
  • Incident-Dialysis
  • Erythropoieitin
  • Erythropoieisis stimulating-agent
  • Roxadustat
  • AZD9941
  • ASP1517
  • FG4592
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has been informed of the nature of this study and has given written in accordance with institutional, local, and national guidelines.
  • Receiving HD or PD for ESRD for a minimum of 2 weeks and a maximum of 4 months, prior to randomization.
  • Hemodialysis access consisting of an arteriovenous (AV) fistula, AV graft, or tunnelled (permanent) catheter; or PD catheter in use.
  • Mean of the two most recent predialysis values during the Screening Period, obtained at least 2 days apart, must be ≤ 10.0 g/dL, with a difference of ≤ 1.3 g/dL between the highest and the lowest values. The last Hb value must be drawn within 10 days prior to randomization.
  • Ferritin ≥ 100 nanograms (ng)/milliliter (mL) (≥ 220 picomoles (pmol)/L); participants with ferritin level \< 100 ng/mL(\<220 pmol/L) during screening, qualify after receiving iron supplement (per local standard of care), without the need to retest ferritin prior to randomization.
  • Transferrin saturation ≥ 20%; participants with TSAT level \< 20% during screening, qualify after receiving iron supplement (per local standard of care), without the need to retest TSAT prior to randomization.
  • Serum folate level, performed within 8 weeks prior to randomization ≥ lower limit of normal (LLN); participants with serum folate level \< LLN during screening, qualify after receiving folate supplement (per local standard of care), without the need to retest folate prior to randomization.
  • Serum vitamin B12 level, performed within 8 weeks prior to randomization ≥ LLN; participants with vitamin B12 level \< LLN during screening, qualify after receiving B12 supplement (per local standard of care), without the need to retest B12 prior to randomization.
  • (ALT) or aspartate aminotransferase (AST) ≤ 3 * (ULN), and total ≤ 1.5 * ULN.
  • Body weight up to 160 kg (HD participants: dry weight).

Exclusion criteria

Exclusion Criteria:

  • Total duration of prior effective ESA use must be ≤3 weeks within the preceding 12 weeks at the time is obtained.

Specific dosing guidance, depending on the type of ESAs, injected IV or SC within 12 weeks prior to start of screening are as follows:

i) Short-acting ESAs (EPO-alfa or equivalents) - IV: Up to 9 doses, last EPO dose must be ≥2 days prior to start of screening; SC: Up to 3 doses, last EPO dose must be ≥1 week (7 days) prior to start of screening ii) Darbepoetin - IV: Up to 3 doses, last darbepoetin dose must be ≥1 week (7 days) prior to start of screening; SC: Up to 2 doses, last darbepoetin dose must be ≥2 weeks (14 days) prior to start of screening iii) Continuous erythropoietin receptor activator (CERA) IV and SC: Up to 2 doses; last CERA dose must be ≥2 weeks (14 days) prior to start of screening

  • Intravenous iron: there is no restriction regarding IV iron use during screening, provided it is administered in accordance with local SOC.
  • Red blood cell transfusion within 4 weeks prior to randomization.
  • Active, infection that could be manifested by white blood cell (WBC) count > , and/or fever, in conjunction with clinical signs or symptoms of infection at the time of randomization.
  • History of chronic liver disease (for example, chronic infectious hepatitis, chronic auto-immune liver disease, cirrhosis, or fibrosis of the liver).
  • Class III or IV congestive heart failure at screening.
  • Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event within a major vessel (excluding vascular dialysis access) (for example, deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization.
  • Uncontrolled hypertension, in the opinion of the Investigator, (for example, that requires a change in anti-hypertensive medication) within 2 weeks prior to randomization.
  • Renal imaging performed within 12 weeks prior to randomization indicative of a diagnosis or suspicion (for example, complex kidney cyst of Bosniak Category 2 or higher) of renal cell carcinoma.
  • History of , except for the following: cancers determined to be cured or in remission for ≥ 5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps.
  • Positive for any of the following: (HIV); surface antigen (HBsAg); or anti- virus antibody (anti-HCV Ab).
  • Chronic inflammatory disease that could impact erythropoiesis (for example, systemic lupus erythematosus, rheumatoid arthritis, celiac disease) even if it is currently in remission.
  • Known, untreated proliferative diabetic retinopathy, diabetic macular edema, macular degeneration, or retinal vein occlusion (participants who are already blind for the above reasons qualify to participate).
  • Known history of myelodysplastic syndrome or multiple myeloma.
  • Known hereditary hematologic disease such as thalassemia or sickle cell anemia, pure red cell aplasia, or other known causes for anemia other than chronic kidney disease (CKD).
  • Known hemosiderosis, hemochromatosis, coagulation disorder, or a hypercoagulable condition.
  • Organ transplant: participants with any of the following:

    1. Experienced rejection of a transplanted organ within 6 months of transplantation
    2. Currently on high doses of therapy (per discretion of the Investigator)
    3. Scheduled for organ transplantation. Note: being on a waiting list for kidney transplant is not exclusionary
  • Anticipated elective surgery, except for vascular access surgery or dialysis catheter placement, that is expected to lead to significant blood loss, or anticipated elective coronary revascularization.
  • Active or chronic gastrointestinal bleeding.
  • Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
  • Use of iron-chelating agents within 4 weeks prior to randomization.
  • Known reaction to any ESA.
  • Use of an drug or treatment, participation in an investigational study, or presence of an expected carryover effect of an investigational treatment, within 4 weeks prior to randomization.
  • Anticipated use of dapsone or androgens at any dose amount or chronic use of acetaminophen or paracetamol > 2.0 g/day during the study.
  • History of alcohol or drug abuse within 6 months prior to randomization.
  • Females of , unless using as detailed in the protocol; male participants with sexual partners of childbearing potential who are not on birth control unless the male participant agrees to use contraception.
  • Pregnant or breastfeeding females.
  • Any medical condition that, in the opinion of the Investigator, may pose a safety risk to a participant in this study, may confound efficacy or safety assessment, or may interfere with study participation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,043 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight \[≤70 kilograms (kg)\] and high weight \[\>70 to 160 kg\] participants will receive 70 and 100 milligrams \[mg\] roxadustat, respectively). Dose adjustment to achieve correction and subsequent maintenance of target hemoglobin (Hb) values (10-12 grams \[g\]/deciliter \[dL\]) will be based upon regular monitoring of Hb. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg per administration (whichever is lower).

    Drug: Roxadustat

  • Active comparator
    Epoetin Alfa

    Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW, with starting doses and dose adjustment rules as per United States Package Insert (USPI) or summary of product characteristics (SmPC). Participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC) as per the country-specific product label (USPI or SmPC) or local standard of care (SOC).

    Drug: Epoetin Alfa

Interventions

  • Roxadustat will be administered per dose and schedule specified in the arm.

    Also known as: ASP1517, AZD9941, FG-4592

  • Epoetin alfa will be administered TIW according to the epoetin alfa USPI or SmPC, or local SOC.

    Also known as: Procrit, Epogen

06

What researchers measure

Primary outcomes

  1. US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)

    Hb values under the influence of rescue therapy were not censored for the primary analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (erythropoiesis-stimulating agent \[ESA\]) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.

    Time frame: Baseline (Day 1, Week 0), Week 28 to 52

  2. Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)

    Hb response was defined, using central laboratory values, as: Hb ≥11.0 g/dL and a Hb increase from baseline by ≥1.0 g/dL in participants whose baseline Hb \>8.0 g/dL, or increase in Hb ≥2.0 g/dL in participants whose baseline Hb ≤8.0 g/dL. Rescue therapy for roxadustat treated participant was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

    Time frame: Baseline (Day 1, Week 0) up to Week 24

Secondary outcomes

  1. US (FDA Submission): Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (ITT Population)

    Hb response was defined, using central laboratory values, as: Hb ≥11.0 g/dL and a Hb increase from baseline by ≥1.0 g/dL in participants whose baseline Hb \>8.0 g/dL, or increase in Hb ≥2.0 g/dL in participants whose baseline Hb ≤8.0 g/dL. Rescue therapy for roxadustat treated participant was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

    Time frame: Baseline (Day 1, Week 0) up to Week 24

  2. Ex-US Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (PPS Population)

    Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.

    Time frame: Baseline (Day 1, Week 0), Week 28 to 52

  3. Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 24

    Baseline LDL Cholesterol was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Week 12 to 24

  4. Mean Change From Baseline in Hb Levels Between Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)

    Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.

    Time frame: Baseline (Day 1, Week 0), Week 18 to 24

  5. Median Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52

    Monthly iron use for each participant = Total IV iron in mg / \[(last dose date - first dose date of study medication in the period)+1\]/ 28.

    Time frame: Weeks 28 to 52

  6. Time to First RBC Transfusion

    Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

    Time frame: Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 227.9 weeks for roxadustat and 226.9 weeks for epoetin alfa)

  7. Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 8 to 12

    Baseline MAP was defined as the last MAP value prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Weeks 8 to 12

  8. Time to First Exacerbation of Hypertension During Weeks 28 to 52

    An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mm Hg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

    Time frame: Weeks 28 to 52

  9. Percentage of Participants With Exacerbation of Hypertension During Weeks 28 to 52

    Percentage of participants with exacerbation of hypertension, meeting at least one of the following criteria are reported: i) Increase in BP: An increase from baseline of ≥ 20 mmHg in sBP and sBP \>170 mmHg, or an increase from baseline of ≥15 mmHg dBP and dBP \>100 mmHg.

    Time frame: Weeks 28 to 52

  10. Time to Achieve the First Hb Response up to Week 24 Censoring for Rescue Therapy

    Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Hb response was defined, using central laboratory values, as: Hb ≥11.0 g/dL and a Hb increase from baseline by ≥1.0 g/dL in participants whose baseline Hb \>8.0 g/dL, or increase in Hb ≥2.0 g/dL in participants whose baseline Hb ≤8.0 g/dL. Rescue therapy for roxadustat treated participant was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Median time to event was calculated using Kaplan Meier Survival Estimates.

    Time frame: Baseline (Day 1, Week 0) up to Week 24

  11. Percentage of Participants With Hb ≥10.0 g/dL Averaged Over Weeks 28 to 36 and 28 to 52, Regardless of Rescue Therapy

    Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.

    Time frame: Weeks 28 to 36 and 28 to 52

  12. Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 36), Censoring for Rescue Therapy

    Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Week 28 to 36

07

Results

Posted Oct 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneRoxadustatEpoetin Alfa
Started522521
Received at least 1 dose of study drug522517
Completed307309
Not completed215212
Withdrew: Death6454
Withdrew: Withdrawal by subject3749
Withdrew: Other than specified3229
Withdrew: Adverse event2922
Withdrew: Kidney transplant2329
Withdrew: Physician decision147
Withdrew: Lack of efficacy61
Withdrew: Site terminated by sponsor513
Withdrew: Lost to follow-up42
Withdrew: Protocol violation16

Outcome measures

PrimaryUS (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)

Hb values under the influence of rescue therapy were not censored for the primary analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (erythropoiesis-stimulating agent \[ESA\]) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.

Time frame:
Baseline (Day 1, Week 0), Week 28 to 52
Reported as:
Mean · g/dL
US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)
g/dLRoxadustatEpoetin Alfa
Baseline8.43 ± 1.0448.46 ± 0.964
Change at Week 28 to 522.57 ± 1.2692.36 ± 1.214
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = 0.0005 · Ls mean difference: 0.18 · 95% CI 0.079 to 0.287ANCOVA with multiple imputation
PrimaryEx-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)

Hb response was defined, using central laboratory values, as: Hb ≥11.0 g/dL and a Hb increase from baseline by ≥1.0 g/dL in participants whose baseline Hb \>8.0 g/dL, or increase in Hb ≥2.0 g/dL in participants whose baseline Hb ≤8.0 g/dL. Rescue therapy for roxadustat treated participant was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

Time frame:
Baseline (Day 1, Week 0) up to Week 24
Reported as:
Number · percentage of participants
Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)
percentage of participantsRoxadustatEpoetin Alfa
Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)88.284.4
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Responder rate difference: 3.5 · 95% CI -0.7 to 7.7
SecondaryUS (FDA Submission): Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (ITT Population)

Hb response was defined, using central laboratory values, as: Hb ≥11.0 g/dL and a Hb increase from baseline by ≥1.0 g/dL in participants whose baseline Hb \>8.0 g/dL, or increase in Hb ≥2.0 g/dL in participants whose baseline Hb ≤8.0 g/dL. Rescue therapy for roxadustat treated participant was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

Time frame:
Baseline (Day 1, Week 0) up to Week 24
Reported as:
Number · percentage of participants
US (FDA Submission): Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (ITT Population)
percentage of participantsRoxadustatEpoetin Alfa
US (FDA Submission): Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (ITT Population)84.379.5
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Responder rate difference: 4.3 · 95% CI -0.1 to 8.7
SecondaryEx-US Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (PPS Population)

Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.

Time frame:
Baseline (Day 1, Week 0), Week 28 to 52
Reported as:
Mean · g/dL
Ex-US Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (PPS Population)
g/dLRoxadustatEpoetin Alfa
Baseline8.43 ± 1.0438.43 ± 0.963
Change at Week 28 to 522.62 ± 1.2922.44 ± 1.209
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Mixed Models Analysis · p = 0.0148 · Ls mean difference: 0.16 · 95% CI 0.032 to 0.296
SecondaryMean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 24

Baseline LDL Cholesterol was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Week 12 to 24
Reported as:
Mean · mg/dL
Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 24
mg/dLRoxadustatEpoetin Alfa
Baseline109.12 ± 38.833109.22 ± 35.914
Change at Weeks 12 to 24-23.80 ± 29.996-5.39 ± 26.164
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -18.34 · 95% CI -21.448 to -15.232
SecondaryMean Change From Baseline in Hb Levels Between Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)

Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.

Time frame:
Baseline (Day 1, Week 0), Week 18 to 24
Reported as:
Mean · g/dL
Mean Change From Baseline in Hb Levels Between Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)
g/dLRoxadustatEpoetin Alfa
Baseline8.54 ± 0.9688.38 ± 0.961
Change at Week 18 to 242.34 ± 1.2562.48 ± 1.271
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = 0.8178 · Ls mean difference: 0.02 · 95% CI -0.171 to 0.217ANCOVA multiple imputation
SecondaryMedian Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52

Monthly iron use for each participant = Total IV iron in mg / \[(last dose date - first dose date of study medication in the period)+1\]/ 28.

Time frame:
Weeks 28 to 52
Reported as:
Median · mg/PEM
Median Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52
mg/PEMRoxadustatEpoetin Alfa
Median Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 520.00 (0.0 to 1600.0)26.86 (0.0 to 717.7)
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Rank ANCOVA · p = 0.00028 (Threshold for significance at 0.05 level.)
SecondaryTime to First RBC Transfusion

Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

Time frame:
Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 227.9 weeks for roxadustat and 226.9 weeks for epoetin alfa)
Reported as:
Median · weeks
Time to First RBC Transfusion
weeksRoxadustatEpoetin Alfa
Time to First RBC TransfusionNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Cox Proportional Hazards model · p = 0.3284 · Hazard ratio (hr): 1.26 · 95% CI 0.791 to 2.016
SecondaryMean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 8 to 12

Baseline MAP was defined as the last MAP value prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Weeks 8 to 12
Reported as:
Mean · millimeters of mercury (mmHg)
Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 8 to 12
millimeters of mercury (mmHg)RoxadustatEpoetin Alfa
Baseline99.33 ± 10.14699.04 ± 9.874
Change at Weeks 8 to 12-0.12 ± 8.0181.15 ± 8.729
SecondaryTime to First Exacerbation of Hypertension During Weeks 28 to 52

An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mm Hg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

Time frame:
Weeks 28 to 52
Reported as:
Median · weeks
Time to First Exacerbation of Hypertension During Weeks 28 to 52
weeksRoxadustatEpoetin Alfa
Time to First Exacerbation of Hypertension During Weeks 28 to 52NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Exacerbation of Hypertension During Weeks 28 to 52

Percentage of participants with exacerbation of hypertension, meeting at least one of the following criteria are reported: i) Increase in BP: An increase from baseline of ≥ 20 mmHg in sBP and sBP \>170 mmHg, or an increase from baseline of ≥15 mmHg dBP and dBP \>100 mmHg.

Time frame:
Weeks 28 to 52
Reported as:
Number · percentage of participants
Percentage of Participants With Exacerbation of Hypertension During Weeks 28 to 52
percentage of participantsRoxadustatEpoetin Alfa
Percentage of Participants With Exacerbation of Hypertension During Weeks 28 to 5214.015.2
SecondaryTime to Achieve the First Hb Response up to Week 24 Censoring for Rescue Therapy

Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Hb response was defined, using central laboratory values, as: Hb ≥11.0 g/dL and a Hb increase from baseline by ≥1.0 g/dL in participants whose baseline Hb \>8.0 g/dL, or increase in Hb ≥2.0 g/dL in participants whose baseline Hb ≤8.0 g/dL. Rescue therapy for roxadustat treated participant was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Median time to event was calculated using Kaplan Meier Survival Estimates.

Time frame:
Baseline (Day 1, Week 0) up to Week 24
Reported as:
Median · weeks
Time to Achieve the First Hb Response up to Week 24 Censoring for Rescue Therapy
weeksRoxadustatEpoetin Alfa
Time to Achieve the First Hb Response up to Week 24 Censoring for Rescue Therapy7.1 (6.1 to 8.1)8.1 (8.1 to 9.1)
SecondaryPercentage of Participants With Hb ≥10.0 g/dL Averaged Over Weeks 28 to 36 and 28 to 52, Regardless of Rescue Therapy

Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.

Time frame:
Weeks 28 to 36 and 28 to 52
Reported as:
Number · percentage of participants
Percentage of Participants With Hb ≥10.0 g/dL Averaged Over Weeks 28 to 36 and 28 to 52, Regardless of Rescue Therapy
percentage of participantsRoxadustatEpoetin Alfa
Weeks 28 to 3673.470.8
Weeks 28 to 5273.672.5
SecondaryMean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 36), Censoring for Rescue Therapy

Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Week 28 to 36
Reported as:
Mean · g/dL
Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 36), Censoring for Rescue Therapy
g/dLRoxadustatEpoetin Alfa
Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 36), Censoring for Rescue Therapy2.70 ± 1.4232.46 ± 1.308

Adverse events

Collected over Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 227.9 weeks for roxadustat and 226.9 weeks for epoetin alfa). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 227.9 weeks for roxadustat and 226.9 weeks for epoetin alfa).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat64/522 (12.3%)234/522 (44.8%)291/522 (55.7%)
Epoetin Alfa54/517 (10.4%)218/517 (42.2%)262/517 (50.7%)
Most frequent serious events
Showing 10 of 400
Most frequent serious events
EventRoxadustatEpoetin Alfa
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications39/52221/517
PneumoniaInfections and infestations30/52226/517
SepsisInfections and infestations13/5228/517
PeritonitisInfections and infestations12/52212/517
Fluid overloadMetabolism and nutrition disorders9/52212/517
Hypertensive crisisVascular disorders9/52212/517
Acute myocardial infarctionCardiac disorders6/52211/517
Device related infectionInfections and infestations9/5223/517
Cardiac failure congestiveCardiac disorders5/5227/517
DeathGeneral disorders2/5227/517
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRoxadustatEpoetin Alfa
HypertensionVascular disorders96/52287/517
DiarrheaGastrointestinal disorders72/52238/517
Muscle spasmsMusculoskeletal and connective tissue disorders60/52239/517
HeadacheNervous system disorders57/52243/517
HyperphosphatemiaMetabolism and nutrition disorders52/52235/517
HypotensionVascular disorders49/52233/517
NauseaGastrointestinal disorders45/52230/517
Arteriovenous fistula site complicationInjury, poisoning and procedural complications27/52242/517
ConstipationGastrointestinal disorders35/52223/517
VomitingGastrointestinal disorders32/52217/517

Baseline characteristics

The Intention-to-Treat (ITT) population included all randomized participants.

Age, Categorical
Age, Categorical(Participants)RoxadustatEpoetin AlfaTotal
<=18 years000
Between 18 and 65 years381391772
>=65 years141130271
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatEpoetin AlfaTotal
Female213214427
Male309307616
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RoxadustatEpoetin AlfaTotal
Hispanic or Latino9977176
Not Hispanic or Latino423444867
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RoxadustatEpoetin AlfaTotal
Race — White415400815
Race — Black/African American445094
Race — Asian435194
Race — Other191635
Race — American Indian/ Alaskan Native145
08

Study locations

113 sites
  • Investigational Site
    Chula Vista, California 91910, United States
  • Investigational Site
    La Mesa, California 91942, United States
  • Investigational Site
    San Diego, California 92111, United States
  • Investigational Site
    Coral Springs, Florida 33071, United States
  • Investigational Site
    Lauderdale Lakes, Florida 33313-1638, United States
  • Investigational Site
    Miami, Florida 33143, United States
  • Investigational Site
    Miami, Florida 33173, United States
  • Investigational Site
    Tampa, Florida 33614, United States
  • Meridian
    Meridian, Idaho 83642, United States
  • Investigational Site
    Shreveport, Louisiana 71101, United States
  • Investigational Site
    Detroit, Michigan 48236, United States
  • Investigational Site
    Pontiac, Michigan 48341, United States
  • Investigational Site
    Brookhaven, Mississippi 39601, United States
  • Investigational Site
    Columbus, Mississippi 39705, United States
  • Investigational Site
    Gulfport, Mississippi 39501, United States
  • Investigational Site
    Tupelo, Mississippi 38801, United States
  • Investigational Site
    Saint Ann, Missouri 63074, United States
  • Investigational Site
    Saint Louis, Missouri 63136, United States
  • Investigational Site
    Portsmouth, New Hampshire 38815, United States
  • Investigational Site
    Albuquerque, New Mexico 87109, United States
  • Investigational Site
    Durham, North Carolina 27704, United States
  • Investigational Site
    New Bern, North Carolina 28562, United States
  • Investigational Site
    Columbus, Ohio 43215, United States
  • Investigational Site
    Columbia, South Carolina 29203, United States
  • Investigational Site
    Orangeburg, South Carolina 29118, United States
  • Investigational Site
    Sumter, South Carolina 29150, United States
  • Investigational Site
    Knoxville, Tennessee 37923, United States
  • Investigational Site
    Edinburg, Texas 78539, United States
  • Investigational Site
    Houston, Texas 77099, United States
  • Investigational Site
    Houston, Texas 77450, United States
  • Investigational Site
    Serandi, Buenos Aires 1872, Argentina
  • Investigational Site
    Santa Fe, IX Region S3000EPU, Argentina
  • Investigational Site
    Burgas, 8000, Bulgaria
  • Investigational site
    Dobrich, 9300, Bulgaria
  • Investigational site
    Pazardjik, 4400, Bulgaria
  • Investigational site
    Pernik, 2300, Bulgaria
  • Investigational Site
    Pleven, 5800, Bulgaria
  • Investigational Site
    Plovdiv, 4003, Bulgaria
  • Investigational site
    Ruse, 7000, Bulgaria
  • Investigational Site
    Sofia, 1233, Bulgaria
  • Investigational Site
    Sofia, 1407, Bulgaria
  • Investigational site
    Sofia, 1431, Bulgaria
  • Investigational Site
    Sofia, 1504, Bulgaria
  • Invesigational Site
    Stara Zagora, 6000, Bulgaria
  • Investigational Site
    Varna, 9000, Bulgaria
  • Investigational Site
    Temuco, IX Region 4781151, Chile
  • Investigational Site
    La Serena, Region De Coquimbo 1720421, Chile
  • Investigational Site
    Barranquilla, Atlántico, Colombia
  • Investigational Site
    Barranquilla, Colombia
  • Investigational site
    Goyang-Si, Gyeonggi-do 410-719, Korea, Republic of
  • Investigational Site
    Guri-si, Gyeonggi-do 471-701, Korea, Republic of
  • Investigational Site
    Seongnam-si, Gyeonggi-do 463-712, Korea, Republic of
  • Investigational Site
    Anyang-si, 431-796, Korea, Republic of
  • Investigational Site
    Seoul, 130-872, Korea, Republic of
  • Investigational Site
    Seoul, 134-727, Korea, Republic of
  • Investigational Site
    Riga, LV-1038, Latvia
  • Invetigational Site
    Riga, LV1001, Latvia
  • Investigational Site
    Ventspils, LV3601, Latvia
  • Investigational Site
    Miri, Sarawak 98000, Malaysia
  • Investigational Site
    Alor Setar, 05460, Malaysia
  • Investigational Site
    George Town, 10990, Malaysia
  • Investigational Site
    Kuala Lumpur, 43000, Malaysia
  • Investigational Site
    Kuala Lumpur, 50586, Malaysia
  • Investigational Site
    Taiping, 34000, Malaysia
  • Investigational Site
    Aguascalientes, 20230, Mexico
  • Investigational Site
    San Luis Potosi, 78240, Mexico
  • Investigational Site
    Chorzów, 41-500, Poland
  • Investigational Site
    Golub-Dobrzyń, 87-400, Poland
  • Investigational Site
    Inowroclaw, 88-100, Poland
  • Investigational Site
    Katowice, 40-027, Poland
  • Investigational Drug
    Pruszkow, 05-804, Poland
  • Investigational Site
    Bucharest, District 3 031422, Romania
  • Investigational Site
    Bucharest, 020475, Romania
  • Investigational Site
    Bucharest, 022305, Romania
  • Investigational Site
    Bucharest, 022325, Romania
  • Investigational Site
    Bucharest, 022329, Romania
  • Investigational Site
    Craiova, 200349, Romania
  • Investigational Site
    Slatina, 230108, Romania
  • Investigational Site
    Targu- Mures, 540098, Romania
  • Investigational Site
    Moscow, Russian Ferderation 125284, Russian Federation
  • Investigational Site
    Kaluga, 248007, Russian Federation
  • Investigational Site
    Kolomna, 140407, Russian Federation
  • Investigational Site
    Krasnodar, 350029, Russian Federation
  • Investigational Site
    Krasnodar, 350051, Russian Federation
  • Investigational Site
    Moscow, 115446, Russian Federation
  • investigational Site
    Moscow, 129327, Russian Federation
  • Investigational Site
    NIzhny Novgorod, 603076, Russian Federation
  • Investigational Site
    Novorossiysk, 353915, Russian Federation
  • Investigational site
    Omsk, 644112, Russian Federation
  • Investigational Site
    Orenburg, 460040, Russian Federation
  • Investigational Site
    Petrozavodsk, 185019, Russian Federation
  • Investigational Site
    Rostov-on-Don, 142100, Russian Federation
  • Investigational Site
    Saint-Petersburg, 194354, Russian Federation
  • Investigational Site
    Smolensk, 214006, Russian Federation
  • Investigational Site
    St. Petersburg, 191104, Russian Federation
  • Investigational Site
    St. Petersburg, 192242, Russian Federation
  • Investigational Site
    St. Petersburg, 193318, Russian Federation
  • Investigational Site
    St. Petersburg, 195257, Russian Federation
  • Investigational site
    St. Petersburg, 196247, Russian Federation
  • Investigational Site
    St. Petersburg, 197110, Russian Federation

Showing the first 100 of 113 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Sep 2018, 55 months.

Results were first posted in Oct 2021, 3 years after primary completion. A results delay was requested in Oct 2019.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 55 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2014
First posted
Feb 3, 2014
StartActual
Feb 11, 2014
Primary completionActual
Sep 21, 2018
CompletionActual
Sep 21, 2018
Results delay requested
Oct 23, 2019
Results first posted
Oct 1, 2021
Last update
Oct 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02052310
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Feb 11, 2014
Primary completion
Sep 21, 2018
Completion
Sep 21, 2018
Results posted
Oct 1, 2021
Last update
Oct 1, 2021

Study contacts

Charles Bradley, PhD
study director · FibroGen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion